Allogeneic stem cell transplantation in multiple myeloma: immunotherapy and new drugs

Bibliography

• Engelhardt M, Kleber M, Udi J, et al. Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches. Leuk Lymphoma 2010;51:1424-43
   PubMed Web of Science ®Google Scholar
• Aschan J, Lonnqvist B, Ringden O, et al. Graft-versus-myeloma effect. Lancet 1996;348:46
   Web of Science ®Google Scholar
• Tricot G, Vesole DH, Jagannath S, et al. Graft-versus-myeloma effect: proof of principle. Blood 1996;87:1196-8
   PubMed Web of Science ®Google Scholar
• Le Blanc R, Montminy-Métivier S, Belanger L, et al. Allogeneic transplantation for multiple myeloma: further evidence for a GvHD-associated graft-versus-myeloma effect. Bone Marrow Transplant 2001;28:841-8
   PubMed Web of Science ®Google Scholar
• Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-71
   PubMed Web of Science ®Google Scholar
• Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-98
   PubMed Web of Science ®Google Scholar
• Richardson PG, Blood E, Mitsiades CS, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006;108:3458-64
   PubMed Web of Science ®Google Scholar
• Giaccone L, Storer B, Patriarca F, et al. Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. Blood 2011;117:6721-7
   PubMed Web of Science ®Google Scholar
• Verdonck LF, Lokhorst HM, Dekker AW, et al. Graft-versus-myeloma effect in two cases. Lancet 1996;347:800-1
   PubMed Web of Science ®Google Scholar
• Lokhorst HM, Shattenberg A, Cornelisse JJ, et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol 2000;18:3031-7
   PubMed Web of Science ®Google Scholar
• Bjorkstrand BB, Ljungman P, Svensson H, et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 1996;88:4711-18
   PubMed Web of Science ®Google Scholar
• Corradini P, Voena C, Tarella C, et al. Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. J Clin Oncol 1999;17:208-15
   PubMed Web of Science ®Google Scholar
• Corradini P, Cavo M, Lokhorst H, et al. Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood 2003;102:1927-9
   PubMed Web of Science ®Google Scholar
• Binsfeld M, Beguin Y, Belle L, et al. Estabilishment of a murine graft-versus-myeloma model using allogeneic stem cell transplantation. PLoS One 2014;21:e113764
   Google Scholar
• Storb RF, Champlin R, Riddell SR, et al. Non-myeloablative transplants for malignant disease. Hematology Am Soc Hematol Educ Program 2001;375-91
   PubMedGoogle Scholar
• Kroger N, Shimoni A, Schilling G, et al. Unrelated stem cell transplantation after reduced intensity conditioning for patients with multiple myeloma relapsing after autologous transplantation. Br J Haematol 2010;148:323-31
   PubMed Web of Science ®Google Scholar
• Kumar S, Zhang MJ, Li P, et al. Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis. Blood 2011;118:1979-88
   PubMed Web of Science ®Google Scholar
• Bensinger W, Rotta M, Storer B, et al. Allo-SCT for multiple myeloma: a review of outcomes at a single transplant center. Bone Marrow Transplant 2012;47:1312-17
   PubMed Web of Science ®Google Scholar
• Rotta M, Storer BA, Sahebi F, et al. Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. Blood 2009;113:3383-91
   PubMed Web of Science ®Google Scholar
• Bruno B, Rotta M, Patriarca F, et al. Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo. Blood 2009;113:3375-82
   PubMed Web of Science ®Google Scholar
• Attal M, Harosseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003;349:2495-02
   PubMed Web of Science ®Google Scholar
• Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875-83
   PubMed Web of Science ®Google Scholar
• Martino M, Morabito F. Autologous stem cell transplantation in multiple myeloma is not dead but alive and well. Expert Opin Biol Ther 2014;29:1-6
   Google Scholar
• Palumbo A, Cavallo F, Gay F, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med 2014;371:895-905
   PubMed Web of Science ®Google Scholar
• Bruno B, Rotta M, Patriarca F, et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 2007;356:1110-20
   PubMed Web of Science ®Google Scholar
• Krishnan A, Pasquini MC, Logan B, et al. Tandem autologous versus single autologous transplantation followed by allogeneic hematopoietic cell transplantation for patients with multiple myeloma: results from the blood and marrow transplant clinical trials network (BMT CTN) 0102 trial. Lancet Oncol 2011;12(3):1195-03
   PubMedGoogle Scholar
• Gahrton G, Iacobelli S, Bjorkstrand B, et al. Autologous/reduced-intensity conditioning allogeneic stem cell transplantation versus autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. Blood 2013;121:5055-63
   PubMed Web of Science ®Google Scholar
• Björkstrand B, Iacobelli S, Hegenbart U, et al. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. J Clin Oncol 2011;29:3016-22
   PubMed Web of Science ®Google Scholar
• Michallet M, Sobh M, Iacobelli S, et al. Allogeneic hematopoietic stem cell transplantation for multiple myeloma: evolution and outcomes over more than two decades within EBMT centers. Blood 2014;2554:abstract
   Google Scholar
• Sahebi F, Shen Y, Thomas SH, et al. Late relapses following reduced intensity allogeneic transplantation in patients with multiple myeloma: a long-term follow-up study. Br J Haematol 2013;160:199-06
   PubMed Web of Science ®Google Scholar
• Vekemans MC, Michaux L, Van Den Neste E, et al. Long term survival after allogeneic stem cell ransplantation for advanced stage multiple myeloma. Br J Haematol 2014;166:616-18
   PubMed Web of Science ®Google Scholar
• Lokhorst HM, Van Der Holt B, Cornelisse JJ, et al. Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study. Blood 2012;119:6219-25
   PubMed Web of Science ®Google Scholar
• Devillier R, Versuluis J, Van Der Holt B, et al. The impact of allogeneic stem cell transplantation as part of first line treatment on outcome of patients with multiple myeloma depends on the method of analysis. Blood 2014;1209:abstract
   Google Scholar
• Garban F, Attal M, Michallet M, et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 2006;107:3474-80
   PubMed Web of Science ®Google Scholar
• Moreau P, Garban F, Attal M, et al. Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma. Blood 2008;112:3914-15
   PubMed Web of Science ®Google Scholar
• Rosinol L, Perez-Simon JA, Sureda A, et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood 2008;112:3591-3
   PubMed Web of Science ®Google Scholar
• Knop S, Liebisch P, Hebart H, et al. Autologous followed by allogeneic versus tandem-autologous stem cell transplant in newly diagnosed FISH-del13q myeloma. Blood 2014;43:abstract
   Google Scholar
• Hofmann S, Muller L, Harsdorf S, et al. Survival analysis in patients with multiple myeloma after allogeneic hematopoietic stem cell transplantation, a single center study (1994-2013). 2014;124:1233
   Google Scholar
• Donato ML, Siegel DS, Vesole DH, et al. The graft-versus-myeloma effect: chronic graft-versus-host disease but not acute graft-versus-host diseaseprolongs survival in patients with multiple myeloma receiving allogeneic transplantation. Biol Blood Marrow Transplant 2014;20:1211-16
   PubMed Web of Science ®Google Scholar
• Kharfan-Dabaja M, Hamadani M, Reljic T, et al. Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. J Hematol Oncol 2013;6:2
   PubMed Web of Science ®Google Scholar
• Armeson KE, Hill EG, Costa LJ, et al. Tandem autologous vs autologous plus reduced intensity allogeneic transplantation in the upfront management of multiple myeloma: meta-analysis of trials with biological assignment. Bone Marrow Transplant 2013;48(4):562-7
   PubMed Web of Science ®Google Scholar
• Barlogie B, Desikan R, Eddlemon P, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: Identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001;98:492-4
   PubMed Web of Science ®Google Scholar
• Glasmacher A, Hahn C, Hoffmann F, et al. A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol 2006;132:584-93
   PubMed Web of Science ®Google Scholar
• Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004;127:165-72
   PubMed Web of Science ®Google Scholar
• Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-17
   PubMed Web of Science ®Google Scholar
• Richardson PG, Schlossman RL, Berenson J, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002;100:3063-7
   PubMed Web of Science ®Google Scholar
• Harousseau JL, Attal M, Avet-Loiseau H, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol 2010;28:4621-9
   PubMed Web of Science ®Google Scholar
• Popat R, Oakervee HE, Hallam S, et al. Bortezomib, doxorubicin and dexamethasone (PAD) frontline treatment of multiple myeloma: updated results after long-term follow-up. Br J Haematol 2008;141:512-16
   PubMed Web of Science ®Google Scholar
• El Cheick J, Crocchiolo R, Boher JM, et al. Allogeneic transplant for myeloma in the era of new drugs: have the outcomes improved? Leuk Lymphoma 2012;43:1630-2
   Google Scholar
• Kneppers E, van der Holt B, Kersten MJ, et al. Lenalidomide maintenance following non-myeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 trial. Blood 2011;118:2413-19
   PubMed Web of Science ®Google Scholar
• Kroger N, Zabelina T, Klyuchnikov E, et al. Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients. Bone Marrow Transplant 2013;48:403-7
   PubMed Web of Science ®Google Scholar
• Wolschke C, Stubig T, Hegenbart U, et al. Postallograft lenalidomide induces strong NK cell–mediated antimyeloma activity and risk for T cell–mediated GvHD: Results from a phase I/II dose-finding study. Exp Hematol 2013;41:134-42
   PubMed Web of Science ®Google Scholar
• Alsina M, Becker PS, Zhong X, et al. Lenalidomide maintenance for high risk multiple meyloma after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2014;20:1183-9
   PubMed Web of Science ®Google Scholar
• Mohty M, Attal M, Bulabois CE, et al. Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myélome (IFM) and the Société Française de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC). Bone Marrow Transplant 2005;35:165-9
   PubMed Web of Science ®Google Scholar
• Biagi JJ, Mileshkin L, Grigg AP, et al. Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogeneic transplantation. Bone Marrow Transplant 2001;28:1145-50
   PubMed Web of Science ®Google Scholar
• Kroger N, Shimoni A, Zagrivnaja M, et al. Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma. Blood 2004;104(10):3361-3
   PubMed Web of Science ®Google Scholar
• van de Donk NW, Kroger N, Zagrivnaja M, et al. Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma. Blood 2006;107:3415-16
   PubMed Web of Science ®Google Scholar
• El-Cheikh J, Michallet M, Nagler A, et al. High response rate and improved GvHD following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma. Haematologica 2008;93:455-8
   PubMed Web of Science ®Google Scholar
• Bruno B, Patriarca F, Sorasio S, et al. Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation. Haematologica 2006;91:837-9
   PubMed Web of Science ®Google Scholar
• Giaccone L, Sorasio R, Patriarca F, et al. Bortezomib after allografting in multiple myeloma: association between neurotoxicity and cyclosporine treatment. Biol Blood Marrow Transplant 2007;13:497-9
   PubMed Web of Science ®Google Scholar
• Palumbo A, Miguel JS, Sonneveld P, et al. Lenalidomide: a new therapy for multiple myeloma. Cancer Treat Rev 2008;34:283-91
   PubMed Web of Science ®Google Scholar
• Montefusco V, Spina F, Zamagni E, et al. A Case-Matched Analysis Comparing Lenalidomide After Autologous or After Allogeneic Stem Cell Transplantation Demonstrates a Survival Advantage in Allografted Myeloma Patients. Proceedings of the American Society of Hematology meeting, Blood 2012;120:1960
   Google Scholar
• Coman T, Bachy E, Michallet M, et al. Lenalidomide as salvage treatment for multiple myeloma relapsing after allogeneic hematopoietic stem cell transplantation: a report from the French Society of Bone Marrow and Cellular Therapy. Haematologica 2013;98:776-83
   PubMed Web of Science ®Google Scholar
• Minnema MC, Van der Veer MS, Aarts T, et al. Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+ Foxp3+ T cells. Leukemia 2009;23:605-7
   PubMed Web of Science ®Google Scholar
• El Cheick J, Crocchiolo R, Furst S, et al. Lenalidomide plus donor-lymphocytes infusion after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with high risk multiple myeloma. Exp Hematol 2012;40:521-7
   PubMed Web of Science ®Google Scholar
• Bensinger WI, Green DJ, Burwick N, et al. A prospective study of lenalidomide monotherapy for relapse after allo-SCT for multiple myeloma. Bone Marrow Transplant 2014;49:492-5
   PubMed Web of Science ®Google Scholar
• Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357:2133-42
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2123-32
   PubMed Web of Science ®Google Scholar
• Lioznov M, El-Cheikh J, Hoffmann F, et al. Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44+) and T (HLA-DR+) cells. Bone Marrow Transplant 2010;45:349-53
   PubMed Web of Science ®Google Scholar
• Linhares YPL, Pavletic S, Gale RP, et al. Chronic GvHD: Where are we? Where do we want to be? Will immunomodulatory drugs help? Bone Marrow Transplant 2013;48:203-9
   PubMed Web of Science ®Google Scholar
• Flowers ME, Martin PJ. Evaluation of thalidomide for treatment or prevention of chronic graft-versus-host disease. Leuk Lymphoma 2003;44:1141-6
   PubMed Web of Science ®Google Scholar
• Wolff D, Schleuning M, von Harsdorf S, et al. Consensus conference on clinical practice in chronic GvHD: second-line treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2011;17:1-17
   PubMed Web of Science ®Google Scholar
• Vogelsang GB, Farmer ER, Hess AD, et al. Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med 1992;326:1055-8
   PubMed Web of Science ®Google Scholar
• Parker PM, Chao N, Ademanee A, et al. Thalidomide as salvage therapy for chronic graft-versus-host disease. Blood 1995;86:3604-9
   PubMed Web of Science ®Google Scholar
• Browne PV, Weisdorf DJ, et al. Response to thalidomide therapy in refractory chronic graft-versus-host disease. Bone Marrow Transplant 2000;26(8):865-9
   PubMed Web of Science ®Google Scholar
• Kulkarni S, Powles R, DeFor T, et al. Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease. Bone Marrow Transplant 2003;32:165-70
   PubMed Web of Science ®Google Scholar
• Koc S, Leisenring W, Flowers ME, et al. Thalidomide for treatment of patients with chronic graft-versus-host disease. Blood 2000;96(12):3995-6
   PubMed Web of Science ®Google Scholar
• Arora M, Wagner JE, Flowers ME, et al. Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus host disease. Biol Blood Marrow Transplant 2001;7:265-73
   PubMed Web of Science ®Google Scholar
• Chu J, He S, Deng Y, et al. Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells. Clin Cancer Res 2014;20(15):3989-00
   PubMed Web of Science ®Google Scholar
• Pusic I, DiPersio JF, Goran SL, et al. Pomalidomide (POM) in advanced corticosteroid-resistant chronic graft-versus-host disease (cGvHD) [abstract]. Biol Blood Marrow Transplant 2010;16:S311
   PubMedGoogle Scholar
• Li N, Zhao D, Kirschbaum M, et al. HDAC inhibitor reduces cytokine storm and facilitates induction of chimerism that reverses lupus in anti-CD3 conditioning regimen. Proc Natl Acad Sci USA 2008;105:4796-801
   PubMed Web of Science ®Google Scholar
• Reddy P, Sun Y, Toubai T, et al. Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. J Clin Invest 2008;118:2562-73
   PubMed Web of Science ®Google Scholar
• Choi SW, Braun T, Chang L, et al. Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogenei hemopoietic stem-cell transplantation: a phase 1/2 trial. Lancet Oncol 2014;15:87-95
   PubMed Web of Science ®Google Scholar
• Wang D, Iclozan C, Liu C, et al. LBH589 enhances T cell activation in vivo and accelerates graft-versus-host disease in mice. Biol Blood Marrow Transplant 2012;18:1182-90
   PubMed Web of Science ®Google Scholar
• Maes K, De Smedt E, Kassambara A, et al. In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma. Oncotarget 2015;6(5):3319-34
   PubMedGoogle Scholar
• Sun K, Welniak LA, Panoskaltsis-Mortari A, et al. Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc Natl Acad Sci USA 2004;101:8120-5
   PubMed Web of Science ®Google Scholar
• Sun K, Wilkins DE, Anver MR, et al. Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GvHD): delayed administration of bortezomib results in increased GvHD-dependent gastrointestinal toxicity. Blood 2005;106:3293-9
   PubMed Web of Science ®Google Scholar
• Li Z, Wu Q, Yan Z, et al. The protection and therapy effects of bortezomib in murine acute graft-versus-host disease. Transplant Proc 2013;45(6):2527-35
   PubMed Web of Science ®Google Scholar
• Matsumoto M, Yamada T, Yan Z, et al. Essential role of NF-kappa B-inducing kinase in T cell activation through the TCR/CD3 pathway. J Immunol 2002;169:1151-8
   PubMed Web of Science ®Google Scholar
• Barkett M, Gilmore TD. Control of apoptosis by Rel/NF-kappaB transcription factors. Oncogene 1999;18:6910-24
   PubMed Web of Science ®Google Scholar
• Koreth J, Stevenson KE, Kim HT, et al. Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors. Blood 2009;114(18):3956-9
   PubMed Web of Science ®Google Scholar
• Mateos-Mazon J, Perez-Simon JA, Kim HT, et al. Use of bortezomib in the management of chronic graft-versus-host disease among multiple myeloma patients relapsing after allogeneic transplantation. Haematologica 2007;92:1295-6
   PubMed Web of Science ®Google Scholar
• Bruggemann M, Gokbuget N, Kneba M, et al. Acute lymphoblastic leukemia: monitoring minimal residual disease as a therapeutic principle. Semin Oncol 2012;39:47-57
   PubMed Web of Science ®Google Scholar
• Bruggemann M, Raff T, Kneba M. Has MRD monitoring superseded other prognostic factors in adult ALL? Blood 2012;120:4470-81
   PubMed Web of Science ®Google Scholar
• Bassan R, Spinelli O, Oldani E, et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood 2009;113:4153-62
   PubMed Web of Science ®Google Scholar
• Fonseca R, Bergsagel PL, Drach J, et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009;23:2210-21
   PubMed Web of Science ®Google Scholar
• Hoering A, Crowley J, Shaughnessy JDJr, et al. Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapyprotocols. Blood 2009;114:1299-05
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommendationsfor the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel. Blood 2011;117:4691-5
   PubMed Web of Science ®Google Scholar
• Mateo G, Montalban MA, Vidriales MB, et al. Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformlytreated with high-dose therapy. J Clin Oncol 2008;26:2737-44
   PubMed Web of Science ®Google Scholar
• Kumar S, Flinn IW, Richardson PG, et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood 2012;119:4375-82
   PubMed Web of Science ®Google Scholar
• Paiva B, Gutierrez NC, Rosinol L, et al. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood 2012;119:687-91
   PubMed Web of Science ®Google Scholar
• Giaccone L, Brunello L, Passera R, et al. Immunophenotypic response after allografting in multiple myeloma. Bone Marrow Transplant 2015;10.1038/bmt.2014.319
   PubMed Web of Science ®Google Scholar
• Ladetto M, Bruggemann M, Monitillo L, et al. Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders. Leukemia 2013;28:1299-07
   PubMed Web of Science ®Google Scholar
• Cavo M, Terragna C, Martinelli G, et al. Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiplemyeloma. Blood 2000;96:355-7
   PubMed Web of Science ®Google Scholar
• Martinelli G, Terragna C, Zamagni E, et al. Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. J Clin Oncol 2000;18:2273-81
   PubMed Web of Science ®Google Scholar
• Galimberti S, Benedetti E, Morabito F, et al. Prognostic role of minimal residual disease in multiple myeloma patients after nonmyeloablative allogeneic transplantation. Leuk Res 2005;29:961-6
   PubMed Web of Science ®Google Scholar
• Bruno B, Ferrero S, Drandi D, et al. Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma. Proceedings of the American Society of Hematology meeting: Blood; 2014;124:44
   Google Scholar
• Ferrero S, Ladetto M, Drandi D, et al. Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics’ impact on survival. Leukemia 2015;29:689-95
   PubMed Web of Science ®Google Scholar
• Faham M, Zheng J, Moorhead M, et al. Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood 2012;120:5173-80
   PubMed Web of Science ®Google Scholar
• Garfall AL, Volg DT, Weiss BM, et al. Cellular immunotherapy for plasma cell myeloma. Bone Marrow Transplant 2013;48:1377-86
   PubMed Web of Science ®Google Scholar
• Rosenblatt J, Vasir B, Uhl L, et al. Vacconation with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Blood 2011;117(2):393-402
   PubMed Web of Science ®Google Scholar
• Lavenga H, Schaap N, Maas F, et al. Partial T cell-depleted allogeneic stem cell transplantation following reduced-intensity conditioning creates a platform for immunotherapy with donot lymphocyte infusion and recipient dendritic cell vaccination in multiple myeloma. Biol Blood Marrow Transplant 2010;16:320-32
   PubMed Web of Science ®Google Scholar
• Tyler EM, Jungbluth AA, O’Reilly RJ, et al. WT1-specific T-cell responses in high risk multiple myeloma patients undergoing allogeneic T cell-depleted hematopoietic cell transplantation and donor lymphocyte infusions. Blood 2013;121:308-17
   PubMed Web of Science ®Google Scholar
• Garfall AL, Fraietta JA, Maus MV, et al. Immunotherapy with chimeric antigen receptor for multiple myeloma. Discov Med 2014;17:37-46
   PubMedGoogle Scholar
• Cheadle EJ, Sheard V, Hombach AA, et al. Chimeric antigen receptors for T-cell based therapy. Methods Mol Biol 2012;907:645-66
   PubMedGoogle Scholar
• Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011;365:725-33
   PubMed Web of Science ®Google Scholar
• Kochenderfer JM, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012;119:2709-20
   PubMed Web of Science ®Google Scholar
• Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor–modified T cells for acute lymphoid leukemia. N Engl J Med 2013;368:1509-18
   PubMed Web of Science ®Google Scholar
• Peinert S, Prince HM, Guru PM, et al. Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen. Gene Ther 2010;17:678-86
   PubMed Web of Science ®Google Scholar
• Carpenter RO, Evbuomwan MO, Pittaluga S, et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res 2013;19:2048-60
   PubMed Web of Science ®Google Scholar
• Mihara K, Bhattacharyya J, Kitanaka A, et al. T-cell immunotherapy with a chimeric receptor against CD38 is effective in eliminating myeloma cells. Leukemia 2012;26:365-7
   PubMed Web of Science ®Google Scholar
• Casucci M, Nicolis di Robilant B, Falcone L, et al. CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. Blood 2013;122:3461-72
   PubMed Web of Science ®Google Scholar
• Cheng M, Chen Y, Xiao W, et al. NK cell-based immunotherapy for malignant diseases. Cell Mol Immunol 2013;10:230-52
   PubMed Web of Science ®Google Scholar
• Chu J, Deng Y, Benson DM, et al. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia 2014;28:917-27
   PubMed Web of Science ®Google Scholar
• Jiang H, Zhang W, Shang P, et al. Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells. Mol Oncol 2014;8:297-10
   PubMed Web of Science ®Google Scholar
• Ritchie DS, Neeson PJ, Khot A, et al. Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. Mol Ther 2013;21:2122-9
   PubMed Web of Science ®Google Scholar
• Morgan RA, Yang JC, Kitano M, et al. Case report of a serious adverse event following the administration of T cells transduced with chimeric antigen receptor recognizing ERBB2. Mol Ther 2010;18:843-51
   PubMed Web of Science ®Google Scholar
• Blank CI, Brown AC, Peterson M, et al. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res 2004;64:1140-5
   PubMed Web of Science ®Google Scholar
• Kearl TJ, Jing W, Gershan JA, et al. Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma. J Immunol 2013;190:5620-8
   PubMed Web of Science ®Google Scholar
• Saha A, Aoyama K, Taylor PA, et al. Host programmed death lignad 1 is dominant over programmed death ligand 2 espression in regulating graft-versus-host disease lethality. Blood 2013;122:3062-73
   PubMed Web of Science ®Google Scholar
• Caballero-Velazquez T, Lopez-Corral L, Encinas C, et al. Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post)-allogeneic transplantation for high-risk myeloma patients. Br J Haematol 2012;162:474-82
   Web of Science ®Google Scholar
• Beitinjaneh AM, Saliba R, Bashir Q, et al. Durable responses after donor lymphocyte infusion for patients with residual multiple myeloma following non-myeloablative allogeneic stem cell transplant. Leuk Lymphoma 2012;53:1525-9
   PubMed Web of Science ®Google Scholar
• Koreth J, Stevenson KE, Kim HT, et al. Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation. J Clin Oncol 2012;30:3202-8
   PubMed Web of Science ®Google Scholar
• Richardson P. Allogeneic transplantation in multiple myeloma: a potential renaissance in the era of novel therapies? Biol Blood Marrow Transplant 2014;20:1078-9
   PubMed Web of Science ®Google Scholar
• Kroger N, Badbaran A, Lioznov M, et al. Post transplant immunotherapy with donor- lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma. Exp Ematol 2009;37:791-8
   PubMed Web of Science ®Google Scholar